Reach Us +44-1904-929220
Sulphonylureas: Do We Need To Introspect Safety Again? | 3666

Journal of Molecular Biomarkers & Diagnosis
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Sulphonylureas: Do we need to introspect safety again?

2nd World Congress on Biomarkers & Clinical Research

Devindra Sehra, Sudhish Sehra and Shiv Tej Sehra

ScientificTracks Abstracts: J Mol Biomark Diagn

DOI: 10.4172/2155-9929.S1.2

Introduction: Sulphonylureas (SUs) are commonly prescribed medications for type 2 diabetes mellitus (T2DM) worldwide. Diff erences among SUs for kinetic and adenosine triphosphate sensitive potassium (KATP) channels selectivity and consequential extra pancreatic eff ects, though recognized in literature, are not considered by treatment guidelines. Areas Covered: Th e role of SUs in various systems related adverse eff ects have not been well understood. Inconsistencies in literature and lack of clinical trials assessing the long-term eff ects of monotherapy or combination therapy with SUs add to the concern. Th is review provides insights in issues concerning safety of SUs based on literature published between 1980-2011. A comprehensive search was carried out on PubMed, Embase & Cochrane databases using search terms viz. sulphonylureas, sulphonylureas and KATP channels, sulphonylureas & cardiovascular eff ects, sulphonylureas side eff ects etc. Expert Opinion: SUs have been linked to CV events, growth hormone (GH) disorder, malignancy, weight gain and CNS adverse eff ects. Th ese adverse eff ects generally get masked as they are thought to be related to diabetes per se. Th e current article will allow the fraternity to ponder and undertake further research on the ill eff ects of largely prescribed anti-diabetic medication.
Relevant Topics